Trustmark to Acquire Health Fitness Corporation

Acquisition Creates Broad Total Population Health Product Platform, Opportunities for Growth

Trustmark Mutual Holding Company and Health Fitness Corporation (AMEX:FIT) today announced a definitive merger agreement, pursuant to which Trustmark will acquire HealthFitness, an award-winning provider of integrated health and fitness management services, in an all-cash transaction valued at approximately $97 million.

Under the terms of the agreement, Trustmark, through a subsidiary, will commence a tender offer to purchase all outstanding shares of HealthFitness common stock at $8.78 per share in cash. The tender offer price represents a premium of approximately 22% over the closing share price of HealthFitness common stock on January 20, 2010, the last trading day prior to today's announcement, and a premium of approximately 23% over HealthFitness' $7.12 average closing share price for the 30 trading days ended January 20, 2010.

Published: 21 January 2010
Written by Editor
AMEX   Healthcare   Financial Results   Up on News  
Read more: Health Fitness Corporation ( FIT )

QuadraMed Announces Agreement to be Acquired by Francisco Partners

QuadraMed® Corporation (NASDAQ: QDHC), a leading provider of healthcare information technologies and services that help turn quality care into positive financial outcomes, announced that it has entered into a definitive merger agreement to be acquired by Francisco Partners, one of the world’s largest technology-focused private equity firms.

Under the terms of the agreement Francisco Partners has agreed to acquire all of the outstanding shares of QuadraMed’s common stock for $8.50 per share in cash and all of the outstanding shares of QuadraMed’s Series A Cumulative Mandatory Convertible Preferred Stock for $13.7097 per share in cash. The per-share consideration to the Series A Preferred Stock represents the common-equivalent consideration for such Series A Preferred Stock based on its current conversion ratio. The all-cash transaction is valued at approximately $126 million.

Published: 08 December 2009
Written by Editor
Nasdaq   Healthcare   M & A   Up on News  
Read more: QuadraMed ( QDHC )

Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes

Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen’s GeneVa® platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.

Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90% of whom are affected by type 2 diabetes.

Published: 09 November 2009
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Compugen Ltd ( CGEN )

IMS Health to be Acquired by TPG and CPP Investment Board

IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital (“TPG”) and the CPP Investment Board (“CPPIB”) in a transaction with a total value of $5.2 billion, including the assumption of debt.

The agreement was unanimously approved by the IMS Board of Directors based upon the recommendation of the Transaction Committee that was established to undertake a review of IMS’s strategic alternatives. Under the agreement, IMS shareholders will receive $22.00 cash for each share of IMS common stock they own, representing a premium of approximately 50 percent over the closing share price on Friday, October 16, 2009, the last trading day prior to public speculation that IMS was considering its strategic alternatives.

Published: 05 November 2009
Written by Editor
NYSE   Healthcare   M & A   Up on News  
Read more: IMS Health ( RX )

Zargis Cleared as Apple iPhone Developer; Medical Applications for Smartphones Planned

Zargis Medical Corp., a subsidiary of Speedus Corp. (Nasdaq: SPDE) and a spin-off from Siemens Corporate Research (NYSE: SI), today announced that is has been cleared as an Apple(®) iPhone(®) developer and has begun development of medical diagnostic support software and related peripherals for the iPhone and other leading smartphones.

Zargis has identified the handheld environment as a logical delivery platform for its telemedicine and diagnostic software initiatives, and with its team of experienced developer's plans to leverage the smartphone platform as a mobile hub between medical device peripherals and computer-aided diagnostic support located either locally or remotely.

Published: 21 October 2009
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Speedus Corp ( SPDE )
  1. Allion Healthcare Inc ( ALLI )
  2. Merge Healthcare Incorporated ( MRGE )
  3. etrials Worldwide Inc ( ETWC )
  4. Conseco Inc ( CNO )
  5. Omnicell Inc ( OMCL )